Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 150 of 384

TitleTypeExpected publication date
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Elafibranor for treating primary biliary cholangitis [ID6331]Technology appraisal guidanceTBC
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Technology appraisal guidance
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240Technology appraisal guidanceTBC
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guideline
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Endoscopic duodenal mucosal resurfacing for type 2 diabetesInterventional procedures guidance
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Epiduroscopic lumbar discectomy via the sacral hiatus for sciaticaInterventional procedures guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]Technology appraisal guidanceTBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Technology appraisal guidanceTBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Technology appraisal guidanceTBC
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidance
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Technology appraisal guidanceTBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)NICE guideline
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]Technology appraisal guidance
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidance
Fertility problems: assessment and treatmentNICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidance
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]Technology appraisal guidanceTBC
Flow tDCSMedtech innovation briefingsTBC
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]Highly specialised technology
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidance
Gefapixant for treating refractory or unexplained chronic cough [ID3789]Technology appraisal guidanceTBC
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)Medical technologies guidanceTBC
GID-MT563 NPi-200 for pupillary light reflex in critical care patientsMedical technologies guidanceTBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic painMedical technologies guidanceTBC
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323Technology appraisal guidanceTBC
Glaucoma - lerdelimumab (CAT-152) [ID383]Technology appraisal guidanceTBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidanceTBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Technology appraisal guidanceTBC
Harmful gambling: identification, assessment and managementNICE guideline
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic deviceDiagnostics guidance
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]Technology appraisal guidanceTBC
Ibrutinib for untreated mantle cell lymphoma [ID1221]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All